Gene Therapy Initiative

Displaying 1 – 5 of 5 Articles (1 of 1 Page)

Exciting Updates to Gene Therapy Initiative Presented at Annual Meeting

Recently, we brought together nine research teams for our first-ever in-person Gene Therapy Initiative Annual Meeting.
Read More

Gilbert Family Foundation Furthers Commitment to Curing Neurofibromatosis (NF), Invests Additional $18 Million Toward Gene Therapy Initiative

The Gilbert Family Foundation is excited to announce a new round of three-year grants in the Gene Therapy Initiative to support the development of curative therapies that address the underlying cause of NF1.
Read More

Seeking a True Cure: Developing Gene Replacement and Editing Therapies to Address the Cause of NF1

GFF's Gene Therapy Initiative seeks to explore and develop gene-targeting therapeutic strategies for neurofibromatosis type 1 (NF1) that address the underlying cause of the disease. Targeting the mutated gene itself could yield a more effective, comprehensive response for a greater range of patients.
Read More

Nothing Nonsensical About Nonsense Mutations: GTI Researchers Target One of the Most Common Types of NF1 Disease-Causing Genetic Mutations

While more than 1000 different mutations of the neurofibromatosis type 1 (NF1) gene have been identified to cause the disease, 1 in 5 are classified as "nonsense mutations". Several projects in GFF's Gene Therapy Initiative are exploring and identifying potential therapeutics to address NF1 nonsense mutations.
Read More

Gilbert Family Foundation Announces $12 Million Gene Therapy Initiative to Address Underlying Cause of NF1

The Gilbert Family Foundation's seeks to eradicate neurofibromatosis type 1 (NF1). With our first initiative, we plan to accelerate the development of curative therapies that address the underlying genetic abnormalities in NF1 patients.
Read More